Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients

Journal of Nuclear Medicine

Volumn 50, Issue 2, 2009, Pages 178-183

  Roy, Félix Nicolas ^a   Beaulieu, Sylvain ^a   Boucher, Luc ^a   Bourdeau, Isabelle ^a   Cohade, Christian ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Diabetes; Endocrinology; FDG; Hyperglycemia; Insulin; Oncology; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DIABETIC PATIENT; DIAGNOSTIC ACCURACY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG MUSCLE LEVEL; DRUG SAFETY; DRUG UPTAKE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUTEUS MAXIMUS MUSCLE; HEART MUSCLE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; BLOOD GLUCOSE; CLINICAL PROTOCOLS; DIABETES COMPLICATIONS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; INJECTIONS, INTRAVENOUS; INSULIN; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 59249104293     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.056283     Document Type: Article

References (32)

1. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med. 1993;34:1-6.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care. 2004;27:1047-1053.
3. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology. 1992;183:643-647.
4. Zhuang HM, Cortes-Blanco A, Pourdehnad M, et al. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun. 2001;22:1123-1128.
5. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355-359.
6. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030-1033.
7. Chang YC, Yen TC, Ng KK, et al. Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer? Eur J Nucl Med Mol Imaging. 2005;32:647-652.
8. 18F]FDG standardised uptake values in lung cancer? Eur J Nucl Med Mol Imaging. 2002;29:1324-1327.
9. Torizuka T, Zasadny KR, Wahl RL. Diabetes decreases FDG accumulation in primary lung cancer. Clin Positron Imaging. 1999;2:281-287.
10. Torizuka T, Fisher SJ, Wahl RL. Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-D-glucose into experimental mammary carcinoma. Radiology. 1997;203:169-172.
11. Turcotte E, Leblanc M, Carpentier A, Bénard F. Optimization of whole-body positron emission tomography imaging by using delayed 2-deoxy-2-[F-18]fluoro-D-glucose injection following i.v. insulin in diabetic patients. Mol Imaging Biol. 2006;8:348-354.
12. 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885-895.
13. Bombardieri E, Aktolun C, Baum RP, et al. FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:BP115-BP124.
14. Torizuka T, Clavo AC, Wahl RL. Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. J Nucl Med. 1997;38:382-386.
15. Minn H, Nuutila P, Lindholm P, et al. In vivo effects of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma. Cancer. 1994;73:1490-1498.
16. Torizuka T, Fisher SJ, Brown RS, Wahl RL. Effect of insulin on uptake of FDG by experimental mammary carcinoma in diabetic rats. Radiology. 1998;208:499-504.
17. Zhao S, Kuge Y, Tsukamoto E, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med. 2001;28:730-735.
18. Williams KV, Bertoldo A, Mattioni B, Price JC, Cobelli C, Kelley DE. Glucose transport and phosphorylation in skeletal muscle in obesity: insight from a muscle-specific positron emission tomography model. J Clin Endocrinol Metab. 2003;88:1271-1279.
19. Yokoyama I, Yonekura K, Ohtake T, et al. Role of insulin resistance in heart and skeletal muscle F-18 fluorodeoxyglucose uptake in patients with noninsulin-dependent diabetes mellitus. J Nucl Cardiol. 2000;7:242-248.
20. Kelley DE, Mintun MA, Watkins SC, et al. The effect of noninsulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest. 1996;97:2705-2713.
21. Kelley DE, Williams KV, Price JC. Insulin regulation of glucose transport and phosphorylation in skeletal muscle assessed by PET. Am J Physiol. 1999; 277:E361-E369.
22. Williams KV, Price JC, Kelley DE. Interactions of impaired glucose transport and phosphorylation in skeletal muscle insulin resistance: a dose-response assessment using positron emission tomography. Diabetes. 2001;50:2069-2079.
23. Williams KV, Bertoldo A, Kinahan P, Cobelli C, Kelley DE. Weight loss-induced plasticity of glucose transport and phosphorylation in the insulin resistance of obesity and type 2 diabetes. Diabetes. 2003;52:1619-1626.
24. Kemppainen J, Stolen K, Kalliokoski KK, et al. Exercise training improves insulin stimulated skeletal muscle glucose uptake independent of changes in perfusion in patients with dilated cardiomyopathy. J Card Fail. 2003;9:286-295.
25. Fujimoto T, Kemppainen J, Kalliokoski KK, Nuutila P, Ito M, Knuuti J. Skeletal muscle glucose uptake response to exercise in trained and untrained men. Med Sci Sports Exerc. 2003;35:777-783.
26. Hallsten K, Virtanen KA, Lonnqvist F, et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone. Diabet Med. 2004;21:1280-1287.
27. Yokoyama I, Yonekura K, Moritan T, et al. Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients. J Nucl Med. 2001;42:1005-1010.
28. 18F-FDG PET study. J Nucl Med. 2003;44:682-689.
29. Iozzo P, Hallsten K, Oikonen V, et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care. 2003;26:2069-2074.
30. Iozzo P, Hallsten K, Oikonen V, et al. Insulin-mediated hepatic glucose uptake is impaired in type 2 diabetes: evidence for a relationship with glycemic control. J Clin Endocrinol Metab. 2003;88:2055-2060.
31. Iozzo P, Lautamaki R, Geisler F, et al. Nonesterified fatty acids impair insulin-mediated glucose uptake and disposition in the liver. Diabetologia. 2004; 47:1149-1156.
32. 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med. 2005;46:1531-1536.